NDATOPICALAEROSOL, FOAM
Approved
May 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
16
Data completeness
7/8 — Comprehensive
FABIOR (tazarotene) by Design Pharmaceuticals is form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Approved for acne vulgaris. First approved in 2012.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FABIOR (tazarotene) is a topical retinoid that selectively binds retinoic acid receptors (RARβ and RARγ) to treat acne vulgaris and psoriasis through anti-hyperproliferative and anti-inflammatory effects. Delivered as an aerosol foam formulation, it normalizes skin differentiation and reduces corneocyte accumulation. The drug is also being studied for hand-foot skin reactions associated with targeted oncology agents and other dermatologic conditions.
$0.079MPart D
Peak3.8 years to LOEFABIOR is in peak lifecycle with modest Part D penetration (61 claims in 2023), suggesting niche positioning and a smaller commercial team relative to blockbuster-class dermatology competitors.
Mechanism of Action
form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Tazarotenic acid binds to all 3 members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ and RARγ and may modify gene expression. The clinical…
Pharmacologic Class:
Retinoid
Indications (1)
Clinical Trials (16)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Started Aug 2017
155 enrolled
Acne Vulgaris
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
Started Feb 2014
66 enrolled
Nail Psoriasis
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
Started Jun 2010
59 enrolled
Acne Vulgaris
Worked on FABIOR at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.